Innocan Pharma Recognizes Dr. Joseph Pergolizzi
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology sectors, has proudly announced that Dr. Joseph V. Pergolizzi, Jr., a key member of its Scientific Advisory Board, has earned a remarkable distinction. He has been recognized among the top 2% of most-cited scientists globally, according to a recent publication by Stanford University. This extraordinary honor highlights Dr. Pergolizzi's substantial and ongoing contributions to medical science, along with his influential role in advancing healthcare practices worldwide.
Dr. Pergolizzi's Role at Innocan Pharma
Since his appointment to the Scientific Advisory Board in 2023, Dr. Pergolizzi has played a pivotal role in steering Innocan’s research and development efforts. His expertise in pain management and critical care, coupled with his profound understanding of regulatory processes, is instrumental in guiding the company's ambition of filing the necessary approvals with the FDA for new medication. His leadership helps shape innovative solutions that may significantly impact patients' lives.
A Word from the CEO
Expressing the pride of the organization, Iris Bincovich, CEO of Innocan Pharma, shared her enthusiastic perspective on Dr. Pergolizzi's achievement. "We are incredibly proud of Dr. Pergolizzi's well-deserved recognition as one of the most-cited scientists worldwide. His dedication to advancing medical research is palpable, and it has greatly influenced our R&D efforts. We look forward to our continued collaboration as we strive to enhance patients' quality of life through cannabinoid-based therapies and innovative drug delivery solutions," Bincovich added.
About Innocan Pharma Corporation
Innocan is dedicated to advancing the pharmaceutical landscape with a dual focus—Pharmaceuticals and Consumer Wellness. In its Pharmaceuticals segment, Innocan is pioneering drug delivery platform technologies that integrate cannabinoid science to effectively treat multiple health conditions. Among these developments, the LPT CBD-loaded liposome platform stands out, designed to ensure precise dosing and controlled release of CBD into the bloodstream. Currently, this platform is in preclinical trials for Epilepsy and Pain Management, showcasing Inncoan’s commitment to research-driven solutions.
Consumer Wellness Initiative
Innocan's Consumer Wellness segment is equally dynamic, focusing on the creation and marketing of avant-garde self-care products aimed at promoting healthier lifestyles. To enhance its outreach, Innocan has initiated a Joint Venture known as BI Sky Global Ltd., committed to innovating advanced e-commerce strategies in response to growing consumer demand.
Contact Innocan Pharma
For more information about Innocan Pharma’s initiatives and developments, please reach out:
Innocan Pharma Corporation
Iris Bincovich, CEO
Contact Number: +1 5162104025
Additional Numbers: +972-54-3012842, +442037699377
Frequently Asked Questions
What is Innocan Pharma known for?
Innocan Pharma is a pharmaceutical tech company specializing in cannabinoid-based therapies, focusing on drug delivery technologies to improve patient care.
Who is Dr. Joseph Pergolizzi?
Dr. Joseph Pergolizzi is a recognized expert in pain management and a member of Innocan’s Scientific Advisory Board, recently named among the top 2% most-cited scientists globally.
What is the LPT CBD-loaded liposome platform?
The LPT CBD-loaded liposome platform is an innovative technology developed by Innocan to facilitate precise dosing and controlled release of CBD for therapeutic use.
How does Innocan contribute to consumer wellness?
Innocan develops and markets a comprehensive range of self-care products intended to promote healthier lifestyles among consumers.
How can I get in touch with Innocan Pharma?
You can contact Innocan Pharma through their CEO, Iris Bincovich, at the provided phone numbers for inquiries about their offerings and initiatives.
